Hemangiomas are common in infants, and often appear within the first few weeks of life. Although many infant hemangiomas are unsightly but regress after a few months, others can be large and disfiguring. Until recently, there have been no ideal treatment options, but there has been recent success using propranolol to treat infant hemangiomas. Host Dr. Michael Greenberg explores this exciting new treatment with Dr. Buddy Cohen, professor of dermatology and pediatrics at Johns Hopkins University School of Medicine.
Beta-Blockers: New Treatment for Infant Hemangiomas
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Hemangiomas are common in infants, and often appear within the first few weeks of life. Although many infant hemangiomas are unsightly but regress after a few months, others can be large and disfiguring. Until recently, there have been no ideal treatment options, but there has been recent success using propranolol to treat infant hemangiomas. Host Dr. Michael Greenberg explores this exciting new treatment with Dr. Buddy Cohen, professor of dermatology and pediatrics at Johns Hopkins University School of Medicine.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
0.25 credits
<p>Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy</p>
CME/CE
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
0.50 credits
<p>IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement</p>
CME/CE
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
0.25 credits
<p>IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
CME/CE
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
0.50 credits
<p><span data-contrast="auto" xml:lang="EN-US">Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow</span><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'> </span></p>
CME/CE
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
1.00 credits
<p>Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers</p>
CME/CE
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
<p>FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?